The Hall Family Foundation and Sunderland Foundation donated $150 million to accelerate pediatric research, increasing space by nearly six times. The new research institute will house top researchers and enable precise diagnoses and treatments for complex childhood diseases.
Children's Mercy has developed a groundbreaking app called CHAMP to monitor single-ventricle babies, reducing mortality rates and improving patient care. The program uses Microsoft devices and services to track vital signs and trigger alerts for instant evaluation.
Researchers at Children's Mercy Kansas City have achieved a 26-hour turnaround time for rapid whole-genome sequencing and genetic diagnosis in critically-ill infants, known as STAT-Seq. This technology can identify mutations associated with approximately 5,300 known genetic diseases.
A study at Children's Mercy Hospital demonstrates the potential of rapid whole-genome sequencing in diagnosing genetic diseases in critically ill infants. The STAT-Seq test improved diagnosis rates to over half, leading to refined clinical care and improved treatment outcomes.
Researchers identified high blood pressure, protein loss, and anemia as predictors of disease worsening in children with mild to moderate CKD. Intervening on these modifiable risk factors may change the long-term course of the disease, preventing kidney failure and delaying dialysis or transplantation.
Researchers at Children's Mercy Hospital identified the CLPB gene associated with a new pediatric mitochondrial syndrome, characterized by cataracts, psychomotor regression, epilepsy, and death in early childhood. The discovery demonstrates the importance of basic research into human CPLB gene function and paves the way for diagnosing ...
A new study published in Science Translational Medicine confirms the benefits of genomic medicine in diagnosing children with neurologic disorders. Genomic testing has ended diagnostic odysseys for families, leading to changes in clinical impressions and management, while also reducing wait times by over six years.
A new tablet-based app called CHAMP is connecting single ventricle heart defect patients to their doctors for real-time monitoring. The app has shown promising results in reducing mortality rates and decreasing the burden on caregivers.
The American Academy of Pediatrics has issued updated policy statements recommending improved research and education on the treatment of children in urgent care centers. The guidelines emphasize the need for timely evaluation, stabilization, and transfer of children with emergencies, as well as consistent oversight and quality monitoring.
The updated guidelines emphasize a multidisciplinary approach to care, targeting growth, neurocognitive development, quality of life, and risk for complications. Children's Mercy Hospital has led the Chronic Kidney Disease in Children study, identifying factors that lead to kidney disease progression in children.
The American Academy of Pediatrics (AAP) has updated its policy on the off-label use of drugs in children, offering guidance for physicians to ensure safe and effective treatment. The new recommendations aim to improve drug safety and efficacy in pediatric patients, particularly those with special needs or rare diseases.
A nationwide study led by Children's Mercy researcher found that adding a monoclonal antibody called gemtuzumab to standard chemotherapy significantly reduced the risk of relapse and increased disease-free survival rates in children with acute myeloid leukemia (AML). The treatment was most effective in patients at high risk of relapse.
Children's Mercy Hospital will assess the benefits of rapid genome sequencing in diagnosing acutely ill babies, with a focus on improving speed and cost-effectiveness. The grant aims to evaluate the use of STAT-Seq technology to help physicians make timely diagnoses and provide families with answers quickly.
Children's Mercy researchers developed STAT-Seq, a 50-hour whole genome sequencing approach, to diagnose critically ill infants. The technology could reduce hospitalization and costs by quickly identifying genetic diseases, with potential benefits for up to one-third of NICU patients.